Sangamo Therapeutics has initiated an auction process for its ST-503 program, a clinical-stage treatment targeting chronic neuropathic pain from small fiber neuropathy, with completion expected in Q4 2026. The program has FDA Fast Track status and shows promise in reducing pain by targeting the Nav1.7 sodium channel. Meanwhile, Sangamo closed previous asset sales to PTC Therapeutics and Eli Lilly, generating $163.55 million in cash proceeds, which were used to repay outstanding financing. These moves are part of Sangamo's ongoing Chapter 11 reorganization efforts to stabilize its business and focus on key assets.
Sangamo Therapeutics is advancing its ST-503 program with an auction process expected to conclude in Q4 2026. Eli Lilly, a recent buyer of Sangamo assets, trades on Pluang at USD 1,166.00 as of Oct 14, 2026 03:11 WIB, with a 1-day change of -1.41%. The stock shows a market cap of $1.05 trillion and a typical hold time of 94 days on the platform.
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
